The pharmacodynamic effect of sirolimus: Individual variation of cytokine mRNA expression profiles in human whole blood samples

Immunobiology

Volumn 214, Issue 1, 2009, Pages 17-26

  Müller Steinhardt, Michael ^a   Wortmeier, Kristina ^b   Fricke, Lutz ^b   Ebel, Brigitte ^b   Härtel, Christoph ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cytokine mRNA expression; Sirolimus; T cell proliferation; Whole blood assay

Indexed keywords

CYCLOSPORIN A; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RAPAMYCIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CASE REPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; EX VIVO STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

AGED; ANTIGENS, CD3; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; T-LYMPHOCYTES;

EID: 58149483654     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2008.04.002     Document Type: Article

References (32)

1. Bertani T., Ferrazzi P., Schieppati A., Ruggenenti P., Gamba A., Parenzan L., Mecca G., Perico N., Imberti O., and Remuzzi A. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int. 40 (1991) 243-250
2. Beveridge T., and Calne R.Y. Cyclosporine (Sandimmun) in cadaveric renal transplantation. Ten-year follow-up of a multicenter trial. European multicentre trial group. Transplantation 59 (1995) 1568-1570
3. Brunetti N.D., Munno I., Pellegrino P.L., Ruggiero V., Correale M., Cuculo A., Campanale G., Mavilio G., Ziccardi L., and Di Biase M. Inflammatory cytokine imbalance after coronary angioplasty: links with coronary atherosclerosis. J. Interv. Cardiol. 20 (2007) 248-257
4. Flechner S.M., Kurian S.M., Solez K., Cook D.J., Burke J.T., Rollin H., Hammond J.A., Whisenant T., Lanigan C.M., Head S.R., and Salomon D.R. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am. J. Transpl. 4 (2004) 1776-1785
5. Hackstein H. Rapamycin and dendritic cells: keep on movin'. Transplantation 82 (2006) 739-740
6. Hammers H.J., Kirchner H., and Schlenke P. Ultraviolet-induced detection of halogenated pyrimidines: simultaneous analysis of DNA replication and cellular markers. Cytometry 40 (2000) 327-335
7. Hammers H.J., Saballus M., Sheikzadeh S., and Schlenke P. Introduction of a novel proliferation assay for pharmacological studies allowing the combination of BrdU detection and phenotyping. J. Immunol. Methods 264 (2002) 89-93
8. Härtel C., Bein G., Kirchner H., and Kluter H. A human whole-blood assay for analysis of T-cell function by quantification of cytokine mRNA. Scand. J. Immunol. 49 (1999) 649-654
9. Härtel C., Bein G., Müller-Steinhardt M., and Kluter H. Ex vivo induction of cytokine mRNA expression in human blood samples. J. Immunol. Methods 249 (2001) 63-71
10. Härtel C., Fricke L., Schumacher N., Kirchner H., and Muller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin. Chem. 48 (2002) 2225-2231
11. Härtel C., Schumacher N., Fricke L., Ebel B., Kirchner H., and Müller-Steinhardt M. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin. Chem. 50 (2004) 141-151
12. Hong J.C., and Kahan B.D. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69 (2000) 2085-2090
13. Ikonen T.S., Gummert J.F., Hayase M., Honda Y., Hausen B., Christians U., Berry G.J., Yock P.G., and Morris R.E. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70 (2000) 969-975
14. June C.H., Ledbetter J.A., Lindsten T., and Thompson C.B. Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J. Immunol. 143 (1989) 153-161
15. Jung U., Foley J.E., Erdmann A.A., Toda Y., Borenstein T., Mariotti J., and Fowler D.H. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol. Blood Marrow Transplant. 12 (2006) 905-918
16. Kahan B.D., Gibbons S., Tejpal N., Chou T.C., and Stepkowski S. Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. Transplant. Proc. 23 (1991) 1090-1091
17. Kahan B.D., Gibbons S., Tejpal N., Stepkowski S.M., and Chou T.C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51 (1991) 232-239
18. Kirchner H., Kleinicke C., and Digel W. A whole-blood technique for testing production of human interferon by leukocytes. J. Immunol. Methods 48 (1982) 213-219
19. Lai J.H., and Tan T.H. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J. Biol. Chem. 269 (1994) 30077-30080
20. Larson T.S., Dean P.G., Stegall M.D., Griffin M.D., Textor S.C., Schwab T.R., Gloor J.M., Cosio F.G., Lund W.J., Kremers W.K., Nyberg S.L., Ishitani M.B., Prieto M., and Velosa J.A. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am. J. Transplant. 6 (2006) 514-522
21. Libetta C., Sepe V., Zucchi M., Portalupi V., Meloni F., Rampino T., and Dal Canton A. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney Int. 72 (2007) 114-120
22. Lindstein T., June C.H., Ledbetter J.A., Stella G., and Thompson C.B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244 (1989) 339-343
23. Ma K.L., Ruan X.Z., Powis S.H., Moorhead J.F., and Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) 2721-2728
24. Mathew T., Kreis H., and Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin. Transplant. 18 (2004) 446-449
25. Pascual M., Swinford R.D., Ingelfinger J.R., Williams W.W., Cosimi A.B., and Tolkoff-Rubin N. Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol. Today 19 (1998) 514-519
26. Pham P.T., Pham P.C., Danovitch G.M., Ross D.J., Gritsch H.A., Kendrick E.A., Singer J., Shah T., and Wilkinson A.H. Sirolimus-associated pulmonary toxicity. Transplantation 77 (2004) 1215-1220
27. Robey E., and Allison J.P. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol. Today 16 (1995) 306-310
28. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31 (1998) 335-340
29. Sordi V., Bianchi G., Buracchi C., Mercalli A., Marchesi F., D'Amico G., Yang C.H., Luini W., Vecchi A., Mantovani A., Allavena P., and Piemonti L. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation 82 (2006) 826-834
30. Terada N., Lucas J.J., Szepesi A., Franklin R.A., Domenico J., and Gelfand E.W. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J. Cell Physiol. 154 (1993) 7-15
31. Webster A.C., Lee V.W., Chapman J.R., and Craig J.C. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst. Rev. 19 2 (2006) CD004290
32. Yatscoff R., LeGatt D., Keenan R., and Chackowsky P. Blood distribution of rapamycin. Transplantation 56 (1993) 1202-1206